Clinical trial

Early Reduction of Post-opeRative Pain and Inflammation to Expedite Return to Function After KNEE Arthroscopy

Name
63476
Description
The purpose of this study is to determine if ceftriaxone administered postoperatively via intravenous injection reduces postoperative visual analog scale (VAS) pain scores and narcotic consumption in patients undergoing knee arthroscopy for a cartilage or meniscal injury.
Trial arms
Trial start
2021-12-28
Estimated PCD
2022-04-29
Trial end
2022-04-29
Status
Terminated
Phase
Early phase I
Treatment
Ceftriaxone
single intravenous dose of 1 g of ceftriaxone
Arms:
Experimental
Placebo
1% lidocaine and saline
Arms:
Placebo
Other names:
Lidocaine and Saline
Size
5
Primary endpoint
Change in Visual Analog Scale (VAS) Pain Score
Pre-operative, 2 months post-operative
Change in RU SATED Score
Pre-operative, 2 months post-operative
Post-operative Narcotic Use
5-12 days post-operative
Eligibility criteria
Inclusion Criteria: 1. Written consent to participate in the study 2. Male or female greater than or equal to 18 years of age and less than 55 years of age 3. Is indicated for knee arthroscopy for cartilage or meniscal procedure 4. Ambulatory and in good general health 5. Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions. 6. Willing to abstain from use of protocol-restricted medications during the study Exclusion Criteria: 1. Known allergic reactions to cephalosporins 2. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease 3. History of infection in either knee joint 4. Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening 5. Other surgery or arthroscopy of either knee within 6 months of Screening 6. Intraarticular treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation or any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed). 7. Intraarticular treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening 8. Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening 9. Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening 10. Females who are pregnant or nursing or plan to become pregnant during the study; men whose female partner plans to conceive during the study 11. Radiographic osteoarthritic changes defined as Kellgren-Lawrence grade 2 or greater (as determined by PI from patient's preoperative X-rays) 12. Inability to read and understand English 13. Any prior diagnosis of antibiotic-resistant diarrhea
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'After providing informed consent, patients undergoing arthroscopy of the knee for meniscal or cartilage injuries will be randomized into one of two groups. At the time of surgery, while the patient is under anesthesia, one group will receive a single intravenous dose of 1 gram of ceftriaxone and the other will receive a single intravenous dose of 1% lidocaine in saline.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'One group will receive an intravenous dose of ceftriaxone and the other will receive an intravenous dose of lidocaine in saline. The syringes will be blinded to ensure that both the investigator administering the injection and the patient will be blinded to the group assignment.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 5, 'type': 'ACTUAL'}}
Updated at
2023-09-05

1 organization

1 product

3 indications

Organization
Austin V Stone
Indication
Meniscus Tear
Indication
Meniscus Lesion